Unique ID issued by UMIN | UMIN000022719 |
---|---|
Receipt number | R000026119 |
Scientific Title | Clinical trial to evaluate Capsicum annuum L intake on serum glucose level after glucose load in healthy human. |
Date of disclosure of the study information | 2017/06/13 |
Last modified on | 2017/12/21 16:18:36 |
Clinical trial to evaluate Capsicum annuum L intake on serum glucose level after glucose load in healthy human.
Clinical trial with Capsicum annuum L
Clinical trial to evaluate Capsicum annuum L intake on serum glucose level after glucose load in healthy human.
Clinical trial with Capsicum annuum L
Japan |
Healthy person
Adult |
Others
NO
The objective of this study is to evaluate the efficacy of Capsicum annuum L intake on serum glucose level after meal.
Efficacy
glucose level (at min-0, min-30, min-60 and min-120)
AUC of glucose level
Interventional
Cross-over
Randomized
Individual
Open -no one is blinded
Placebo
2
Prevention
Food |
Cooked chilli peppers (Capsicum annuum L)
100 g/meal
Once a day
Placebo containing the three major nutrients
100 g/meal
Once a day
20 | years-old | <= |
60 | years-old | > |
Male and Female
(1) Non smokers
(2) Persons who will generally be judged as healthy
(3) Persons who have never suffered from asthma
(4) Persons who have never developed any allegic reaction to medicines, foods, or other substances.
(5) Persons who will give written informed consent by theirselves
(1) Persons who have any dietary supplements, quasi drugs or medicines which cause same or similar efficacy with the effect evaluated in this study.
(2) Persons who changed their habitats of supplements within 4 weeks.
(3) Persons who work in night shift or in day and night shift.
(4) Persons who have been treated their illness or prevention in a clinic at their informed consent
persons with their medical histories as follows: serious diseases of Sugar metabolism,lipid metabolism, liver function, renal function, heart, circulatory, respiratory, endocrine system, immune system, or mental illness of the nervous system.
(6) Persons with the medical histories of alcoholism or drug dependence.
(7) Prsons who might be developed allergic reaction to foods.
(8) Persons who are pregnant, breast-feeding, or hope to be pregnant during the study period.
(9) Persons who had always participated in or will participate in any other clinical trial (to use foods/medicine/quasi medicine/medical device)
(10) Persons who will not be judged suitable to the participants by the investigator.
10
1st name | |
Middle name | |
Last name | Koichiro Ohnuki |
Kindai University
Department of Biological & Environmental
11-6, Kayanomori, Iizukacity, Fukuoka
0948-22-5655
ohnuki@fuk.kindai.ac.jp
1st name | |
Middle name | |
Last name | Koichiro Ohnuki |
Kindai University
Department of Biological & Environmental
11-6, Kayanomori, Iizukacity, Fukuoka
0948-22-5655
ohnuki@fuk.kindai.ac.jp
Kinki University
Department of Biological & Environmental Chemistry
Faculty of Human-Oriented Science and Engineering
Pharmacy Solutions Co., Ltd.
Profit organization
NO
2017 | Year | 06 | Month | 13 | Day |
Unpublished
Completed
2016 | Year | 06 | Month | 08 | Day |
2016 | Year | 06 | Month | 20 | Day |
2016 | Year | 06 | Month | 13 | Day |
2017 | Year | 12 | Month | 21 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026119